Letter by nezami et al regarding article, "platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the gauging responsiveness with a verify now P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial" by Nezami, N. et al.
Correspondence
Letter by Nezami et al Regarding Article, “Platelet
Reactivity and Cardiovascular Outcomes After
Percutaneous Coronary Intervention: A Time-
Dependent Analysis of the Gauging Responsiveness
With a VerifyNow P2Y12 Assay: Impact on
Thrombosis and Safety (GRAVITAS) Trial”
To the Editor:
Price et al1 have reported the results of the Gauging Responsive-
ness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and
Safety (GRAVITAS) trial in patients who had undergone percuta-
neous coronary intervention with 1 drug-eluting stents for the
treatment of stable coronary artery disease or acute coronary syn-
drome at 83 sites in the United States and Canada. They reported that
achievement of on-clopidogrel reactivity208 P2Y12 reaction units
at 12 to 24 hours after percutaneous coronary intervention/during
follow-up was associated with a lower risk for cardiovascular
events.1
This is a well-designed clinical trial represented by multiple
published articles.2–3 The authors have analyzed and compared the
effect of statins as a covariant in the previously published articles.2
However, although the covariant effects of acute coronary syndrome
presentation, diabetes mellitus, prior myocardial infarction, coronary
artery bypass grafting, percutaneous coronary intervention, creati-
nine clearance, -blocker at discharge, and total stent length were
reported at 60 days and 6 months in the recent study, there is no
result related to statin use and its covariant effect.1
Statins show antiplatelet effects in patients with hypercholester-
olemia and stable coronary artery disease. Ex vivo and in vivo
evaluations showed lower platelet deposition, aggregate size, surface
coverage, and collagen-induced platelet aggregation among statin-
treated patients. The authors of this article conclude that in acute
myocardial infarction patients statins have an early antiplatelet effect
in addition to that afforded by standard antiplatelet therapy.4
Furthermore, clopidogrel (as a prodrug) requires hepatic cyto-
chrome P450 metabolic activation to be converted to the active
metabolite that is able to inhibit the platelet P2Y12 adenosine-
diphosphate receptor, decreasing platelet activation and aggregation
processes. Statins, especially atorvastatin, have been identified that
limit the ability of clopidogrel to inhibit platelet activation and
aggregation processes in pharmacodynamic studies.5
Collectively, it would be helpful if, in their conclusion, the authors
were to provide more information on the intake of statins, types of
statins used, analysis of covariant effect, and the impact of statins on
study outcomes.
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